Effects of nanoparticles on the adhesion and cell viability on astrocytes

Biological Trace Element Research

Volumn 120, Issue 1-3, 2007, Pages 248-256

  Au, Catherine ^a   Mutkus, Lysette ^b   Dobson, Allison ^c   Riffle, Judy ^d   Lalli, Jennifer ^d   Aschner, Michael ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c WINSTON SALEM STATE UNIVERSITY   (United States)

^d NANOSONIC INC   (United States)

Author keywords

Astrocytes; Cell adhesion; Cytotoxicity; Nanoparticles

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; LACTATE DEHYDROGENASE; NANOPARTICLE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ADHESION; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; ENZYME RELEASE; NEUROTOXICITY; NEWBORN; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; ASTROCYTES; CELL ADHESION; CELL SURVIVAL; MAGNETICS; MITOCHONDRIA; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 36048937333     PISSN: 01634984     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12011-007-0067-z     Document Type: Article

References (41)

1. Begley DJ (1996) The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 48:136-146
2. Olivier JC (2005) Drug transport to brain with targeted nanoparticles. NeuroRx 2:108-119
3. Feng SS, Huang GF, Mu L (2000) Nanospheres of biodegradable polymers: a system for clinical administration of an anticancer drug paclitaxel (Taxol). Ann Acad Med Singap 29:633-639
4. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70:1-20
5. Muller BG, Leuenberger H, Kissel T (1996) Albumin nanospheres as carriers for passive drug targeting: an optimized manufacturing technique. Pharm Res 13:32-37
6. Ramge P et al (2000) Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur J Neurosci 12:1931-1940
7. Alyaudtin RN et al (2001) Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J Drug Target 9:209-221
8. Kreuter J et al (2002) Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 10:317-325
9. Calvo P et al (2001) Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 18:1157-1166
10. Olivier JC et al (1999) Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res 16:1836-1842
11. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y (1994) In vitro drug release behavior of D,L-lactide/ glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. J Pharm Sci 83:727-732
12. Chorny M, Fishbein I, Danenberg HD, Golomb G (2002) Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Control Release 83:389-400
13. Polakovic M, Gorner T, Gref R, Dellacherie E (1999) Lidocaine loaded biodegradable nanospheres. II. Modelling of drug release. J Control Release 60:169-177
14. Le Ray AM, Vert M, Gautier JC, Benoit JP (1994) End-chain radiolabeling and in vitro stability studies of radiolabeled poly(hydroxy acid) nanoparticles. J Pharm Sci 83:845-851
15. Li Y et al (2001) PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release 71:203-211
16. Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53:283-318
17. Sahli H et al (1997) Interactions of poly(lactic acid) and poly(lactic acid-co-ethylene oxide) nanoparticles with the plasma factors of the coagulation system. Biomaterials 18:281-288
18. Bazile D et al (1995) Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 84:493-498
19. Moghimi SM, Hunter AC (2001) Capture of stealth nanoparticles by the body's defences. Crit Rev Ther Drug Carri Syst 18:527-550
20. Huwyler J, Wu D, Pardridge WM (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 93:14164-14169
21. Shi N, Boado RJ, Pardridge WM (2001) Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm Res 18:1091-1095
22. Zhang Y, Schlachetzki F, Pardridge WM (2003) Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther 7:11-18
23. Saiyed ZM, Telang SD, Ramchand CD (2003) Application of magnetic techniques in the field of drug discovery and biomedicine. Biomagn Res Technol 1:2
24. Kimelberg HK, Norenberg MD (1989) Astrocytes. Sci Am 260:66-72, 74, 76
25. Abbott NJ, Revest PA, Romero IA (1992) Astrocyte-endothelial interaction: physiology and pathology. Neuropathol Appl Neurobiol 18:424-433
26. Aschner M (1996) Astrocytes as modulators of mercury-induced neurotoxicity. Neurotoxicology 17:663-669
27. Di Monte DA, Royland JE, Irwin I, Langston JW (1996) Astrocytes as the site for bioactivation of neurotoxins. Neurotoxicology 17:697-703
28. Frangakis MV, Kimelberg HK (1984) Dissociation of neonatal rat brain by dispase for preparation of primary astrocyte cultures. Neurochem Res 9:1689-1698
29. Uyeda CT, Eng LF, Bignami A (1972) Immunological study of the glial fibrillary acidic protein. Brain Res 37:81-89
30. Nachlas MM, Margulies SI, Goldberg JD, Seligman AM (1960) The determination of lactic dehydrogenase with a tetrazolium salt. Anal Biochem 1:317-326
31. Korzeniewski C, Callewaert DM (1983) An enzyme-release assay for natural cytotoxicity. J Immunol Methods 64:313-320
32. Decker T, Lohmann-Matthes ML (1988) A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 115:61-69
33. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
34. Cory AH, Owen TC, Barltrop JA, Cory JG (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3:207-212
35. Gumerlock MK, Belshe BD, Madsen R, Watts C (1992) Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review. J Neurooncol 12:33-46
36. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA (1998) Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci 87:1305-1307
37. Koziara JM, Lockman PR, Allen DD, Mumper RJ (2003) In situ blood-brain barrier transport of nanoparticles. Pharm Res 20:1772-1778
38. Muller RH, Keck CM (2004) Drug delivery to the brain-realization by novel drug carriers. J Nanosci Nanotechnol 4:471-483
39. Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65-81
40. Berg JM, Tymoczko JL, Stryer L (2002) Biochemistry, 5th edn. Freeman, New York, pp 465-484
41. Jezek P, Zackova M, Ruzicka M, Skobisova E, Jaburek M (2004) Mitochondrial uncoupling proteins - facts and fantasies. Physiol Res 53(Suppl 1):S199-S211